Resin microspheres containing yttrium-90 (Y-90)

DEVICE2 trials

Sponsors

Sirtex Medical, GrandPharma (China) Co., Ltd.

Conditions

BCLC Stage A Hepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaColorectal NeoplasmsUnresectable Hepatocellular Carcinoma

Unknown Phase

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

Active, not recruitingNCT04736121

Sirtex MedicalBCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma +1

Start: 2021-05-28End: 2026-09-01Updated: 2026-02-03

Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer

Not yet recruitingNCT06079242

GrandPharma (China) Co., Ltd.Colorectal Neoplasms

Start: 2023-10-15End: 2027-04-01Target: 200Updated: 2023-10-13

Related Papers

A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study

BMC Gastroenterology2022-03-2815 citations